Aliases & Classifications for Spondylitis

MalaCards integrated aliases for Spondylitis:

Name: Spondylitis 12 74 54 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:6590
ICD9CM 34 720.8
ICD10 32 M46
UMLS 71 C0029644 C0038012

Summaries for Spondylitis

MalaCards based summary : Spondylitis is related to juvenile ankylosing spondylitis and ankylosing spondylitis 1, and has symptoms including sciatica An important gene associated with Spondylitis is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Indomethacin and Loxoprofen have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Spondylitis is an inflammation of the vertebra. It is a form of spondylopathy. In many cases,... more...

Related Diseases for Spondylitis

Diseases related to Spondylitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1104)
# Related Disease Score Top Affiliating Genes
1 juvenile ankylosing spondylitis 34.6 TNFRSF1B TNF ERAP1
2 ankylosing spondylitis 1 34.2 TNFRSF1B CRP
3 fibromyalgia 32.8 TNF IL6 CRP
4 spondyloarthropathy 1 31.9 TNFRSF1B TNF TAP2 TAP1 NOD2 IL23R
5 juvenile rheumatoid arthritis 31.4 TNFRSF1B TNF LTA IL6 CRP
6 spondylarthropathy 31.1 TNF NOD2 LTA
7 spinal disease 31.1 TNFRSF1B TNF IL6 IL17A ERAP1 CRP
8 synovitis 31.1 TNF IL6 IL17A CRP
9 osteomyelitis 31.0 TNF NOD2 IL6
10 arthropathy 30.9 TNF MICA LTA IL6 HLA-B CRP
11 iridocyclitis 30.8 TNFRSF1B TNF IL6 IL17A HLA-B CRP
12 amyloidosis 30.8 TNF SAA1 IL6 CRP
13 bursitis 30.8 TNFRSF1B TNF CRP
14 conjunctivitis 30.7 TNF IL6 HLA-B
15 urethritis 30.7 TNF IL6 CRP
16 osteoarthritis 30.7 TNF IL6 IL17A CRP
17 septic arthritis 30.7 TNF IL6 CRP
18 myositis 30.6 TNF IL6 IL17A HLA-B
19 chlamydia 30.6 TNF IL6 IL17A CRP
20 interstitial lung disease 30.6 TNF IL6 IL17A CRP
21 pericarditis 30.5 TNF IL6 CRP
22 periodontitis 30.5 TNF IL6 IL17A CRP
23 optic neuritis 30.5 TNF LTA IL6
24 proteasome-associated autoinflammatory syndrome 1 30.5 TNF IL6 IL17A CRP
25 sleep disorder 30.5 TNF IL6 CRP
26 relapsing polychondritis 30.5 IL6 IL17A CRP
27 uveitis 30.4 TNFRSF1B TNF NOD2 LTA IL6 IL17A
28 purpura 30.4 TNF IL6 CRP
29 fasciitis 30.4 TNF LTA IL6 CRP
30 aortitis 30.4 TNFRSF1B TNF IL6 IL17A CRP
31 brucellosis 30.4 TNF SAA1 MICA IL6 IL17A CRP
32 duodenal ulcer 30.3 TNF LTA IL6
33 tendinitis 30.3 TNFRSF1B TNF IL6 CRP
34 meningitis 30.3 TNF IL6 IL17A HLA-B CRP
35 systemic autoimmune disease 30.3 IL6 IL17A CRP
36 enthesopathy 30.3 TNFRSF1B TNF ERAP1 CRP CCR6
37 mental depression 30.3 TNF IL6 CRP
38 transverse myelitis 30.3 TNF IL6 IL17A
39 cerebrovascular disease 30.3 TNF LTA IL6 CRP
40 sapho syndrome 30.3 TNFRSF1B TNF NOD2
41 erysipelas 30.3 TNF IL6 CRP
42 infective endocarditis 30.2 TNF IL6 IL17A CRP
43 retinal vascular disease 30.2 TNF IL6 CRP
44 vasculitis 30.2 TNFRSF1B TNF IL6 IL17A HLA-B CRP
45 apnea, obstructive sleep 30.2 TNF IL6 CRP
46 ankylosis 30.2 TNFRSF1B TNF IL17A ERAP1 CRP CCR6
47 endocarditis 30.2 TNFRSF1B TNF IL6 IL17A CRP
48 tonsillitis 30.2 TNF LTA IL6
49 toxic shock syndrome 30.2 TNF LTA IL6 CRP
50 ileus 30.1 TNF IL6 IL17A CRP

Comorbidity relations with Spondylitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Spondylitis:



Diseases related to Spondylitis

Symptoms & Phenotypes for Spondylitis

UMLS symptoms related to Spondylitis:


sciatica

GenomeRNAi Phenotypes related to Spondylitis according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.55 MICA
2 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.55 HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.55 MICA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.55 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.55 MICA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.55 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.55 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.55 NOD2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.55 NOD2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.55 MICA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.55 HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.55 MICA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.55 HLA-B HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.55 MICA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.55 HLA-C

MGI Mouse Phenotypes related to Spondylitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CCR6 ERAP1 IL17A IL23A IL23R IL6
2 immune system MP:0005387 9.44 CCR6 CRP ERAP1 IL17A IL23A IL23R

Drugs & Therapeutics for Spondylitis

Drugs for Spondylitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
2
Loxoprofen Approved Phase 4 68767-14-6, 80382-23-6 3965
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Aceclofenac Approved, Investigational Phase 4 89796-99-6
5
Pamidronate Approved Phase 4 40391-99-9 4674
6
carbamide peroxide Approved Phase 4 124-43-6
7
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
8
Hydroxychloroquine Approved Phase 4 118-42-3 3652
9
Etanercept Approved, Investigational Phase 4 185243-69-0
10
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
11
Acetaminophen Approved Phase 4 103-90-2 1983
12
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
13 Natriuretic Peptide, Brain Phase 4
14 Tocolytic Agents Phase 4
15 Tripterygium Phase 4
16 Mitogens Phase 4
17 Endothelial Growth Factors Phase 4
18 Cholestyramine Resin Phase 4
19 Antibodies, Monoclonal Phase 4
20 Cyclooxygenase 2 Inhibitors Phase 4
21 Antiprotozoal Agents Phase 4
22 Antiparasitic Agents Phase 4
23 Antimalarials Phase 4
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4
25 Analgesics, Non-Narcotic Phase 4
26 Analgesics Phase 4
27 Cyclooxygenase Inhibitors Phase 4
28 Narcotics Phase 4
29 Antipyretics Phase 4
30 Analgesics, Opioid Phase 4
31
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
32
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
33
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
34 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
35
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
36
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
37
Certolizumab pegol Approved Phase 3 428863-50-7
38
Etoricoxib Approved, Investigational Phase 3 202409-33-4 123619
39
Misoprostol Approved Phase 3 59122-46-2 5282381
40
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
41 Brodalumab Approved, Investigational Phase 3 1174395-19-7
42
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
43
Tofacitinib Approved, Investigational Phase 2, Phase 3 477600-75-2
44
Upadacitinib Approved, Investigational Phase 3 1310726-60-3 58557659
45
tannic acid Approved Phase 3 1401-55-4
46
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
47
Ustekinumab Approved, Investigational Phase 3 815610-63-0
48
Entecavir Approved, Investigational Phase 3 142217-69-4 153941
49
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
50
Rebamipide Investigational Phase 3 90098-04-7

Interventional clinical trials:

(show top 50) (show all 446)
# Name Status NCT ID Phase Drugs
1 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Unknown status NCT02492217 Phase 4 Adalimumab
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
4 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
5 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
6 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
7 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
8 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
9 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
10 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
11 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
12 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
13 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
14 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
15 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
16 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
17 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
18 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
19 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
20 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
21 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
22 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
23 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
24 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
25 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
26 Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation Completed NCT03880968 Phase 4 tapering or discontinuation of etanercept
27 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
28 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Completed NCT02509026 Phase 4
29 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
30 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Completed NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
31 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
32 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
33 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
34 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
35 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
36 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 AIN457/Secukinumab Placebo; Biological: AIN457/Secukinumab
37 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
38 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
39 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
40 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib
41 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
42 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
43 Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu® Completed NCT02364479 Phase 4 50mg Yisaipu;25mg etanercept;Placebo
44 A Multicenter,Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Recruiting NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
45 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Recruiting NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
46 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
47 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Recruiting NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
48 GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC). Recruiting NCT02687724 Phase 4 Golimumab (GLM)
49 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Active, not recruiting NCT02758782 Phase 4 Celecoxib
50 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Not yet recruiting NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)

Search NIH Clinical Center for Spondylitis

Genetic Tests for Spondylitis

Anatomical Context for Spondylitis

MalaCards organs/tissues related to Spondylitis:

40
Bone, T Cells, Testes, Spinal Cord, Lung, Endothelial, Heart

Publications for Spondylitis

Articles related to Spondylitis:

(show top 50) (show all 16553)
# Title Authors PMID Year
1
Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. 61 54
15308523 2004
2
Animal models of inflammatory spinal and sacroiliac joint diseases. 61 54
12951872 2003
3
A rare case of disseminated tuberculosis; multiple intracranial and intramedullary tuberculomas with concurrent tuberculous spondylitis and meningitis. 61
32548312 2020
4
Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort. 61
32166439 2020
5
Combined percutaneous and open instrumentation for thoracolumbar kyphosis correction by two-level pedicle subtraction osteotomy in ankylosing spondylitis. 61
31980911 2020
6
Endoplasmic reticulum aminopeptidase 2 gene single nucleotide polymorphisms in association with susceptibility to ankylosing spondylitis in an Iranian population. 61
32360304 2020
7
Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials? 61
32327428 2020
8
Tuberculous spondylitis following intravesical bcg-instillation in the treatment of transitional cell carcinoma: Case report and systematic review. 61
32480296 2020
9
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. 61
32381562 2020
10
Notch receptors and ligands in inflammatory arthritis - a systematic review. 61
32325090 2020
11
Familial aggregation and heritability of ankylosing spondylitis - a Swedish nested case-control study. 61
31687771 2020
12
Ochronosis of the spine mimicking ankylosing spondylitis successfully treated with anakinra. 61
32147566 2020
13
How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI-based ASDAS formula. 61
31628804 2020
14
Spondyloarthritis evolution: what is in your history? 61
32453039 2020
15
Early detection of ankylosing spondylitis using texture features and statistical machine learning, and deep learning, with some patient age analysis. 61
32464565 2020
16
Influence of therapeutic drugs on different manifestations of renal involvement in 907 Chinese patients with ankylosing spondylitis
. 61
32301698 2020
17
Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. 61
31474599 2020
18
Identification of RELN variant p.(Ser2486Gly) in an Iranian family with ankylosing spondylitis; the first association of RELN and AS. 61
32001840 2020
19
Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: A hospital claims database analysis. 61
32476522 2020
20
Aberrant distribution and function of plasmacytoid dendritic cells in patients with ankylosing spondylitis are associated with unfolded protein response. 61
31961055 2020
21
Effects of Andersson lesion treatment in ankylosing spondylitis: A medical record review study focused on medium- to long-term outcomes. 61
32266777 2020
22
Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable. 61
32572483 2020
23
Consequences of spinal ankylosis on bone trabecular fragility assessed on CT scans in patients with ankylosing spondylitis. A retrospective study. 61
32534203 2020
24
Effect of TNF-inhibitor therapy on spinal structural progression in ankylosing spondylitis patients: A systematic review and meta-analysis. 61
32419337 2020
25
Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). 61
32265295 2020
26
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. 61
32157555 2020
27
Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. 61
30900514 2020
28
Mud-bath treatment of seronegative spondyloarthritis: experience at the Euganean Thermal Area. 61
31342241 2020
29
Rheumatologic Disorders and the Nervous System. 61
32487898 2020
30
Oral health-related quality of life in different rheumatic diseases. 61
32510714 2020
31
Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany. 61
32303994 2020
32
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial. 61
32078145 2020
33
The impact of fatigue on patients with psoriatic arthritis: a multi-center study of the TLAR-network. 61
32564159 2020
34
[Bone remodeling after total hip arthroplasty with anatomic medullary locking prosthesis and its long-term effectiveness]. 61
32538557 2020
35
Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides). 61
32548773 2020
36
Evaluating upadacitinib for the treatment of rheumatoid arthritis. 61
32515665 2020
37
Disseminated Mycobacterium abscessus subsp. massiliense infection in a Good's syndrome patient negative for human immunodeficiency virus and anti-interferon-γ autoantibody: a case report. 61
32563248 2020
38
Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. 61
32513190 2020
39
Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action. 61
32533340 2020
40
Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study. 61
32062827 2020
41
The comparison analysis of clinical and radiological features in SAPHO syndrome. 61
32504191 2020
42
Rheumatological conditions as risk factors for self-harm: A retrospective cohort study. 61
32526099 2020
43
Pentraxin 3: A promising therapeutic target for autoimmune diseases. 61
32534154 2020
44
Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines. 61
32444009 2020
45
Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. 61
32567403 2020
46
B7-H3: A promising therapeutic target for autoimmune diseases. 61
32113615 2020
47
Brucellosis spondylitis. 61
32251793 2020
48
Tuberculosis of the axial skeleton mimicking malignancy. 61
32568293 2020
49
Biologics, spondylitis and COVID-19. 61
32522741 2020
50
Anterior oblique retroperitoneal approach vs posterior transpedicular approach for the treatment of one- or two-level lumbar vertebral osteomyelitis: a retrospective cohort study. 61
32500308 2020

Variations for Spondylitis

Expression for Spondylitis

Search GEO for disease gene expression data for Spondylitis.

Pathways for Spondylitis

Pathways related to Spondylitis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 TNFRSF1B TNF TAP2 TAP1 SAA1 NOD2
2
Show member pathways
13.36 TNFRSF1B TNF LTA IL6 IL23R IL23A
3
Show member pathways
13.26 TNFRSF1B TNF LTA IL6 IL23R IL23A
4
Show member pathways
13.22 TNFRSF1B TNF SAA1 NOD2 LTA IL6
5
Show member pathways
12.8 TNFRSF1B TNF TAP2 TAP1 MICA IL6
6
Show member pathways
12.78 TNF TAP2 TAP1 IL6 HLA-C HLA-B
7 12.73 TNF TAP2 TAP1 LTA IL6 HLA-C
8
Show member pathways
12.72 TNF TAP2 TAP1 MICA LTA IL6
9
Show member pathways
12.55 TNF IL6 IL23R IL23A IL17A
10
Show member pathways
12.54 TNF NOD2 IL6 IL23R IL23A IL17A
11 12.52 TNFRSF1B TNF TAP2 TAP1 IL17A
12 12.3 TNF LTA IL6 HLA-C HLA-B
13
Show member pathways
12.28 TNF SAA1 IL6 CRP
14
Show member pathways
12.28 TNFRSF1B TNF LTA IL6 CCR6
15 12.2 TNF NOD2 IL6 IL23A
16
Show member pathways
12.2 TNF LTA IL6 IL17A HLA-C HLA-B
17 12.11 TAP2 TAP1 HLA-C HLA-B
18 11.92 TNFRSF1B TNF NOD2 LTA IL6
19
Show member pathways
11.88 TNF LTA IL6 IL23R IL17A
20 11.85 TNF IL6 IL23A IL17A
21
Show member pathways
11.85 IL6 IL23R IL23A IL17A
22
Show member pathways
11.83 IL6 IL23R IL23A IL17A
23 11.76 TNFRSF1B TNF SAA1 IL6 IL23R IL23A
24
Show member pathways
11.75 TNFRSF1B TNF LTA
25 11.71 TNF IL6 IL23A
26 11.7 TNF IL6 IL23A
27 11.64 TNF LTA IL23R IL23A IL17A CCR6
28 11.55 TNFRSF1B TNF LTA
29
Show member pathways
11.52 TNFRSF1B TNF LTA
30 11.49 TNFRSF1B TNF IL6
31 11.24 TNF IL6 IL23A IL17A
32 10.99 TNF IL6 CRP
33 10.5 TAP2 TAP1 HLA-C HLA-B ERAP2 ERAP1

GO Terms for Spondylitis

Cellular components related to Spondylitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 TNFRSF1B TNF SOST SAA1 LTA IL6
2 cell surface GO:0009986 9.8 TNF NOD2 MICA HLA-C HLA-B CCR6
3 external side of plasma membrane GO:0009897 9.77 TNF MICA IL23R IL17A CCR6
4 extracellular space GO:0005615 9.65 TNF SOST SAA1 MICA LTA IL6
5 MHC class I protein complex GO:0042612 9.43 HLA-C HLA-B
6 MHC class I peptide loading complex GO:0042824 9.4 TAP2 TAP1
7 TAP complex GO:0042825 9.16 TAP2 TAP1
8 phagocytic vesicle membrane GO:0030670 8.92 TAP2 TAP1 HLA-C HLA-B

Biological processes related to Spondylitis according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.07 SAA1 NOD2 IL23R IL23A HLA-C HLA-B
2 adaptive immune response GO:0002250 10.04 TAP2 TAP1 HLA-C HLA-B ERAP2 ERAP1
3 inflammatory response GO:0006954 9.98 TNFRSF1B TNF IL6 IL23R IL23A IL17A
4 immune system process GO:0002376 9.97 TAP2 TAP1 NOD2 IL23R IL23A HLA-C
5 cellular response to lipopolysaccharide GO:0071222 9.95 TNFRSF1B TNF NOD2 IL6
6 defense response GO:0006952 9.92 TNF TAP1 NOD2 HLA-B
7 defense response to Gram-positive bacterium GO:0050830 9.9 TNF LTA IL6 CRP
8 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.85 TAP2 TAP1 HLA-C HLA-B
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.84 TNF NOD2 IL23A
10 positive regulation of T cell proliferation GO:0042102 9.84 IL6 IL23R IL23A
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 TNF IL6 IL23R IL23A
12 positive regulation of interleukin-6 production GO:0032755 9.83 TNF NOD2 IL6
13 humoral immune response GO:0006959 9.8 TNF LTA IL6 CCR6
14 cytokine-mediated signaling pathway GO:0019221 9.8 TNFRSF1B TNF SAA1 IL6 IL23R IL23A
15 acute-phase response GO:0006953 9.78 SAA1 IL6 CRP
16 positive regulation of T cell mediated cytotoxicity GO:0001916 9.77 IL23R IL23A HLA-B
17 positive regulation of interferon-gamma production GO:0032729 9.76 TNF LTA IL23R IL23A
18 positive regulation of glial cell proliferation GO:0060252 9.73 TNF LTA IL6
19 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.71 TNF NOD2 IL6 IL17A
20 positive regulation of neuroinflammatory response GO:0150078 9.7 TNF IL6
21 detection of bacterium GO:0016045 9.7 NOD2 HLA-B
22 regulation of neuroinflammatory response GO:0150077 9.69 TNFRSF1B IL6
23 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.69 IL23R IL23A
24 peptide transport GO:0015833 9.69 TAP2 TAP1
25 positive regulation of interleukin-17 production GO:0032740 9.69 NOD2 IL23R IL23A
26 positive regulation of T-helper 1 type immune response GO:0002827 9.68 IL23R IL23A
27 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.68 TNF IL17A
28 interleukin-23-mediated signaling pathway GO:0038155 9.68 IL23R IL23A
29 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.68 HLA-C HLA-B
30 positive regulation of natural killer cell proliferation GO:0032819 9.67 IL23R IL23A
31 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.67 HLA-C HLA-B
32 positive regulation of osteoclast differentiation GO:0045672 9.67 TNF IL23R IL23A IL17A
33 positive regulation of T-helper 17 type immune response GO:2000318 9.66 IL23R IL23A
34 positive regulation of activation of Janus kinase activity GO:0010536 9.65 IL23R IL23A
35 negative regulation of lipid storage GO:0010888 9.65 TNF IL6 CRP
36 immune response GO:0006955 9.65 TNFRSF1B TNF MICA LTA IL6 IL23A
37 vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane GO:1990668 9.64 TAP2 TAP1
38 positive regulation of memory T cell differentiation GO:0043382 9.64 IL23R IL23A
39 regulation of tyrosine phosphorylation of STAT protein GO:0042509 9.63 IL23R IL23A
40 positive regulation of NK T cell activation GO:0051135 9.63 IL23R IL23A
41 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.62 TNF LTA
42 positive regulation of T-helper 17 cell lineage commitment GO:2000330 9.61 IL23R IL23A
43 cytosol to ER transport GO:0046967 9.58 TAP2 TAP1
44 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.58 TNF LTA
45 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.46 TAP2 TAP1 ERAP2 ERAP1
46 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.1 TAP2 TAP1 HLA-C HLA-B ERAP2 ERAP1

Molecular functions related to Spondylitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide transmembrane transporter activity GO:1904680 9.46 TAP2 TAP1
2 interleukin-6 receptor binding GO:0005138 9.43 IL6 ERAP1
3 TAP1 binding GO:0046978 9.4 TAP2 TAP1
4 MHC class Ib protein binding GO:0023029 9.37 TAP2 TAP1
5 peptide antigen-transporting ATPase activity GO:0015433 9.32 TAP2 TAP1
6 peptide-transporting ATPase activity GO:0015440 9.26 TAP2 TAP1
7 TAP binding GO:0046977 9.16 HLA-C HLA-B
8 peptide antigen binding GO:0042605 9.13 TAP1 HLA-C HLA-B
9 cytokine activity GO:0005125 9.02 TNF LTA IL6 IL23A IL17A

Sources for Spondylitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....